Novartis Ag ADR (NVS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 09-2023 | 06-2023 | 03-2023 | 12-2022 | 09-2022 | |
| Cash Flows From Operating Activities | |||||
| Net Income | 5,934,000 | 4,421,000 | 2,150,000 | 6,049,000 | 4,734,000 |
| Depreciation Amortization | 6,758,000 | N/A | 1,916,000 | 6,965,000 | 5,171,000 |
| Income taxes - deferred | 812,000 | N/A | N/A | 1,128,000 | N/A |
| Accounts receivable | -1,264,000 | -1,147,000 | -700,000 | N/A | -825,000 |
| Accounts payable and accrued liabilities | -85,000 | 99,000 | 26,000 | N/A | -325,000 |
| Other Working Capital | 15,000 | -1,163,000 | -1,513,000 | -796,000 | -2,620,000 |
| Other Operating Activity | -259,000 | 4,323,000 | 1,078,000 | 890,000 | 3,990,000 |
| Operating Cash Flow | $11,911,000 | $6,533,000 | $2,957,000 | $14,236,000 | $10,125,000 |
| Cash Flows From Investing Activities | |||||
| Change In Deposits | 11,119,000 | 10,948,000 | 10,949,000 | 4,662,000 | 5,559,000 |
| PPE Investments | -581,000 | -371,000 | -150,000 | -758,000 | -554,000 |
| Net Acquisitions | -3,935,000 | -289,000 | -110,000 | -1,276,000 | -1,121,000 |
| Purchase Of Investment | -85,000 | -66,000 | -40,000 | -139,000 | -108,000 |
| Sale Of Investment | 201,000 | 110,000 | 63,000 | 133,000 | 121,000 |
| Purchase Sale Intangibles | 637,000 | -764,000 | -91,000 | -1,153,000 | -961,000 |
| Other Investing Activity | 637,000 | -764,000 | -91,000 | -1,154,000 | -962,000 |
| Investing Cash Flow | $7,356,000 | $9,568,000 | $10,621,000 | $1,468,000 | $2,935,000 |
| Cash Flows From Financing Activities | |||||
| Change In Short Term Borrowing | -128,000 | 290,000 | 999,000 | 252,000 | 1,448,000 |
| Debt Repayment | -2,223,000 | N/A | N/A | -2,575,000 | -2,575,000 |
| Common Stock Issued | 158,000 | 159,000 | N/A | 100,000 | 100,000 |
| Common Stock Repurchased | -7,468,000 | -5,843,000 | -2,886,000 | -10,652,000 | -7,974,000 |
| Dividend Paid | -7,255,000 | -7,255,000 | -7,255,000 | -7,506,000 | -7,506,000 |
| Other Financing Activity | 3,245,000 | -190,000 | -60,000 | -181,000 | -61,000 |
| Financing Cash Flow | $-13,671,000 | $-12,839,000 | $-9,202,000 | $-20,562,000 | $-16,568,000 |
| Exchange Rate Effect | -60,000 | 106,000 | 107,000 | -32,000 | -173,000 |
| Beginning Cash Position | 7,517,000 | 7,517,000 | 7,517,000 | 12,407,000 | 12,407,000 |
| End Cash Position | 12,405,000 | 10,885,000 | 12,000,000 | 7,517,000 | 8,726,000 |
| Net Cash Flow | $4,888,000 | $3,368,000 | $4,483,000 | $-4,890,000 | $-3,681,000 |
| Free Cash Flow | |||||
| Operating Cash Flow | 11,911,000 | 6,533,000 | 2,957,000 | 14,236,000 | 10,125,000 |
| Capital Expenditure | -654,000 | -393,000 | -168,000 | -916,000 | -610,000 |
| Free Cash Flow | 11,257,000 | 6,140,000 | 2,789,000 | 13,320,000 | 9,515,000 |